Abstract
Remarkable activity was observed with lurbinectedin in patients (pts) with relapsed small-cell lung cancer (SCLC) in a phase II Basket trial (Trigo et al. 2020). NCCN guidelines recommend platinum re-challenge if chemotherapy-free interval (CTFI) >180 days (d) based on small clinical trials mostly conducted in the 1980s. Recent data on re-challenge with CTFI >90 d showed overall response rate (ORR) of 45-49% and median overall survival (OS) of 7.5-7.9 months (mo) (Genestreti et al. 2015; Monnet et al.
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
